A detailed history of Nisa Investment Advisors, LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 237 shares of CRDF stock, worth $834. This represents 0.0% of its overall portfolio holdings.

Number of Shares
237
Previous 22 977.27%
Holding current value
$834
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 17, 2025

BUY
$2.31 - $5.35 $496 - $1,150
215 Added 977.27%
237 $1,000
Q3 2024

Oct 24, 2024

BUY
$2.05 - $2.77 $45 - $60
22 New
22 $0
Q2 2022

Aug 03, 2022

SELL
$1.17 - $2.61 $2,492 - $5,559
-2,130 Closed
0 $0
Q1 2022

Apr 29, 2022

SELL
$2.11 - $7.25 $6,752 - $23,200
-3,200 Reduced 60.04%
2,130 $5,000
Q4 2021

Feb 03, 2022

SELL
$5.18 - $7.24 $8,650 - $12,090
-1,670 Reduced 23.86%
5,330 $18,000
Q3 2021

Oct 18, 2021

BUY
$5.01 - $7.58 $35,070 - $53,060
7,000 New
7,000 $47,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $153M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.